Nastech/Ribogene nasal metoclopramide is in Phase III; Nastech raises $16.8 mil. in offering.
Executive Summary
NASTECH/RIBOGENE NASAL METOCLOPRAMIDE AWAITING MARKETING PARTNER for further development of the nasal-formulation anti-emetic for use as an alternative to oral and injectable formulations of metoclopramide (Wyeth-Ayerst's Reglan and generics). Ribogene has conducted one Phase III study of the drug, using the trade name Emitasol. A second Phase III study will be necessary prior to filing an NDA, and Ribogene is seeking a partner before proceeding.